Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study

Abstract

Intranasal Sumatritan new two-way delivery system applied at a dose of 20 mg and 10 mg (vs. placebo) was used in 117 patients to treat migraine. Was found to improve the effectiveness of Sumatriptan 20mg (57%) and 10mg (54%) after 120 minutes compared with placebo.

Side effects in relation to treatment were rare, most "metallic taste" (13/10%).

Keywords

• Sumatriptan
• migraine
• bi-directional nasal delivery
• Nasal spray
• 5-HT1B/1D agonists
• adverse events
• double-blind
• efficacy
• Zolmitriptan
• pharmacokinetics
• tolerability